marked.bio

multi-kinase inhibitor · small molecule

sorafenib

2 active trials across 5 of our biomarkers, targeting VEGFR/RAF/FLT3. Not approved for any biomarker on marked.bio yet.

Also known as BAY 43-9006, Nexavar.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
FLT3 mutation (ITD/TKD) 2 13 Phase 3
ALK fusion 0 1 –
BRAF V600E 0 3 –
KRAS G12C 0 8 –
KRAS G12D 0 8 –

Trials

2 of 25 trials shown

  1. MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

    Recruiting Phase 3 The First Affiliated Hospital of Soochow University Started 2026Primary completion 2028-05 NCT07463651

    gilteritinib FDA EUsorafenib

    …ogy, immunology, cytogenetics, and molecular biology (MICM) typing, and confirmed to have FLT3-ITD mutation;

    FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT), Maintenance Therapy

  2. Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

    Recruiting Phase 2/3 Ruijin Hospital Started 2025Primary completion 2030-03 NCT06972641

    decitabinesorafenibAvastinibvenetoclax

    ARM2 Initial bone marrow gene II sequencing showed FLT3-ITD mutation with or without NPM1 mutation, no TP53 mutation, and no AML/MR.

    FLT3 mutation (ITD/TKD)AML, MDS